Sign in Subscribe

Alex Chompff

Review Examines Resistance Mechanisms to Anti-EGFR Therapies

Skip to content The CRC Digest Review Examines Resistance Mechanisms to Anti-EGFR Therapies A review of cetuximab and panitumumab resistance found that intrinsic resistance often stems from pre-existing KRAS, NRAS, and BRAF mutations, while acquired resistance develops through clonal evolution under therapeutic pressure. (Pharmaceuticals) This content is informational only and

Immunotherapy May Reshape Fertility Counseling for Young Women with CRC

Skip to content The CRC Digest Immunotherapy May Reshape Fertility Counseling for Young Women with CRC A narrative review found that immune checkpoint inhibitors for dMMR/MSI-H colorectal cancer may affect reproductive-age women through direct reproductive uncertainty (including endocrine toxicities and hypothesized, but currently unproven, direct gonadal effects) and potential

Canadian Symposium Highlights Care Gaps for Early-Onset Cancer Patients

Skip to content The CRC Digest Canadian Symposium Highlights Care Gaps for Early-Onset Cancer Patients The 2025 Early Age Onset Cancer Symposium identified critical gaps including diagnostic delays, screening eligibility criteria that no longer reflect current disease epidemiology, and insufficient age-appropriate infrastructure for patients under 50. (Curr Oncol) This content

Polyp Risk Rises with Age in Young Adults, Study Finds

Skip to content The CRC Digest Polyp Risk Rises with Age in Young Adults, Study Finds A retrospective colonoscopy study of 3,959 adults aged 18-44 used Joinpoint regression to identify age inflection points for polyp detection rates, with detection rates for polyps, adenomas, and serrated lesions all rising significantly

Updated Guidelines for Resectable Colorectal Cancer Published

Skip to content The CRC Digest ● REGULATORY Updated Guidelines for Resectable Colorectal Cancer Published The American Society of Surgical Oncology summarized contemporary guidance from NCCN, ESMO, and JSCCR, highlighting recent evolution in molecular characterization (including mismatch repair status), neoadjuvant therapy, and organ-preservation strategies. (Ann Surg Oncol) This content is informational

Spatial Tumor Variation May Explain HER2 Testing Discrepancies

Skip to content The CRC Digest ◇ RESEARCH Spatial Tumor Variation May Explain HER2 Testing Discrepancies A retrospective analysis of 1,343 colorectal cancer cases found that spatial intratumoral heterogeneity in HER2 overexpression contributes to discordance between immunohistochemistry/FISH and next-generation sequencing, with implications for HER2-targeted therapy selection. (Virchows Arch) This

FIT Performance Data Now Available for Adults 55 and Younger

Skip to content The CRC Digest ▪ SCREENING FIT Performance Data Now Available for Adults 55 and Younger A cross-sectional German study of 1,724 participants aged 55 or younger assessed fecal immunochemical test (FIT) diagnostic performance at various fecal hemoglobin cutoffs for detecting advanced neoplasia, addressing a critical data gap

Six-Marker Blood Test Shows Promise for CRC Screening in High-Risk Patients

Skip to content The CRC Digest ▪ SCREENING Six-Marker Blood Test Shows Promise for CRC Screening in High-Risk Patients A prospective study evaluated a multi-target DNA methylation panel (Septin9 region 1, BCAT1, IKZF1, BCAN, VAV3, Septin9 region 2) assessed in plasma samples for colorectal cancer risk stratification, offering a potential non-invasive

CRC Research Update — July 27, 2026

Today's colorectal cancer research highlights

End-of-Life Care Trends Show Shift Toward Home and Hospice

Skip to content The CRC Digest End-of-Life Care Trends Show Shift Toward Home and Hospice Among 75,428 early-onset CRC decedents from 1999-2020, the proportion dying at home or hospice facilities increased from 48.3% to 66.6%, though disparities persist for Black patients. (Journal of Gastrointestinal Cancer) This content